Synendos Secures Innosuisse Funding to Advance Clinical Development of SYT-510
Synendos AG is excited to announce that it has been awarded a grant under the highly competitive Start-Up Innovation Project (SIP) scheme of Innosuisse which aims to support cutting-edge Swiss innovation. The Innosuisse SIP initiative fosters groundbreaking science-based projects with high socioeconomic potential.
The project has a total budget of CHF 2.9 million. This funding will be pivotal to supporting our mission to uncover the potential of our novel SERI mechanism in treating neuropsychiatric disorders such as PTSD, through the study of our Phase 1 candidate, SYT-510 in clinical models of anxiety and stress.
We are grateful to Innosuisse for the recognition and support of our innovative approach.
Comments